.svg){kind=logo}
Schizophrenia is a complex mental health condition that affects about 1 in 100 people in the UK. It can cause hallucinations (seeing or hearing things that aren't there) and delusions (fixed, false beliefs). Additionally, people with schizophrenia may experience social withdrawal, difficulty concentrating, and disorganised thinking.
Schizophrenia is typically treated with a combination of medication and therapy. Antipsychotic medications are the mainstay of treatment, helping to manage symptoms like hallucinations and delusions. Therapies, such as cognitive behavioural therapy (CBT), can equip individuals with coping mechanisms and improve social skills. However, finding the right medication and therapy approach can be a process of trial and error, and some people experience side effects from medications.
MeOmics is revolutionizing the future of schizophrenia treatment by providing a more personalised
approach. We analyze each patient's unique biology, focusing on several key areas:
Cellular Activity: We examine how an individual's nerve cells respond to various stimuli.
Genetics: We study their genetic makeup to identify potential risk factors.
By integrating this information with a patient's medical history, MeOmics can offer
more tailored and effective treatment options.
MeOmics aims to predict the most
effective medications for their specific needs. This personalised approach has the potential to:
Reduce trial-and-error with medication: Finding the right medication faster can lead to quicker symptom relief and improved quality of life.
Minimize side effects: Matching the right medication to a patient's biology can potentially reduce
the risk of unwanted side effects.
Empower patients: Being actively involved in a personalised treatment plan can lead to a greater
sense of control and hope for recovery.
If you or someone you know is experiencing symptoms of schizophrenia, it is important to seek professional help. Here are some resources available in the UK:
